Immatics N.v. · NASDAQ:IMTX
Immatics — PEGS: The Essential Protein Engineering & Cell Therapy Summit 2021
10 slides from Immatics's conference presentation, May 11, 2021
Slide 1: Targeting of Tumor-specific Peptide Antigens with Bispecific T Cell-Engaging Receptor (TCER®) Molecules
© Immatics. Not for further reproduction or distribution. Targeting of Tumor - specific Peptide Antigens with Bispecific T Cell - Engaging Receptor (TCER®) Molecules PEGS: The Essential Protein Engineering & Cell Therapy Summit 2021 Sebastian Bunk , Martin Hofmann, Gabriele Pszolla, Meike Hutt, Fran
Slide 2: Disclaimer
Disclaimer 2 This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and Immatics nor any of its affiliates nor any of its or their control persons, offi
Slide 3: TCER® – Immatics' TCR Bispecifics: Proprietary TCER® Format Consisting of Three Distinct Elements
stability - and affinity - engineered TCR domains for targeting tumor - specific peptides presented by HLA molecules Antibody domains for recruitment of T cells Human IgG Fc region (silenced) for conferring preferential serum half - life, stability and manufacturability stability - and affinity - en
Slide 4: TCER® Unlocks Immunotherapies for Solid Cancers with Targets beyond the Cancer Cell Surface
stability - and affinity - engineered TCR domains for targeting tumor - specific peptides presented by HLA molecules Antibody domains for recruitment of T cells Human IgG Fc region (silenced) for conferring preferential serum half - life, stability and manufacturability Antibody domains for recruitm
Slide 5: TCER® – Superior Proprietary TCR Bispecific Format
TCER® – Superior Proprietary TCR Bispecific Format 5 T C E R ® T cell r ec r ui t ing antibody pHLA t a r g e t ing TCR Fc domain (silenced) with KiH technology Potency and stability of proprietary TCER® format is superior to six alternative TCR Bispecific formats 1 1 Based on comparative preclinica
Slide 6: IMA402 TCER® – PRAME Target Peptide on HLA-A*02
IMA402 TCER® – PRAME Target Peptide on HLA - A*02 Detection of PRAME Peptide and PRAME RNA in Tumor and Normal Tissues 6 PRAME Peptide detection (MS) Normal tissue Cancer tissue PRAME RNA detection in tumor samples (ISH) SqNSCLC Ovarian Cancer Indications Target prevalence [%] Uterine carcinoma 100
Slide 7: IMA402 TCER® – In Vitro Efficacy Assessment
IMA402 TCER® – In Vitro Efficacy Assessment PBMC - mediated Cytotoxicity Against Tumor Cells 0 20 40 60 80 100 0 . 1 1 10 100 1000 10000 TCER Conc. [pM] Lysis [%] Tumor cell line ~500 target pHLA per cell 0 20 40 60 80 100 0 . 1 1 10 100 1000 10000 TCER Conc. [pM] Lysis [%] Tumor cell line ~250 targ
Slide 8: IMA402 TCER® – In Vivo Efficacy Assessment
IMA402 TCER® – In Vivo Efficacy Assessment Anti - Tumor Activity of Four IMA402 Candidates in Subcutaneous Tumor Xenograft in Mice Anti - tumor activity of IMA402 TCER® candidates including complete regressions in tumor xenograft model Treatment schedule T r a n s p la n t a t ion Tumor T r a n s p
Slide 9: IMA402 TCER® – In Vitro Safety Assessment
200 175 150 125 100 75 50 25 0 % Lysis w/o 10 - 1 10 0 10 1 10 2 10 3 10 4 10 5 TCER [pM] 200 175 150 125 100 75 50 25 0 % Lysis w/o 10 - 1 10 0 10 1 10 2 10 3 10 4 10 5 TCER [pM] IMA402 TCER® – In Vitro Safety Assessment IMA402 candidate 1 IMA402 candidate 3 iPSC - derived Cardiomyocytes Tumor cell
Slide 10: Profile of Second TCER® Program – IMA402 Candidates Targeting PRAME
Profile of Second TCER® Program – IMA402 Candidates Targeting PRAME Summary • IMA402 TCER® is directed against PRAME , one of the most frequently expressed intracellular cancer targets for TCR - based therapies • Killing of PRAME - positive cancer cells with a minimum of 1,000 - fold therapeutic win
Immatics — PEGS: The Essential Protein Engineering & Cell Therapy Summit 2021 on 6ix